Mechanisms of growth inhibition by antiestrogens and progestins in human breast and endometrial cancer cells.
Marked changes in both growth factor and proto-oncogene expression occur due to treatment of hormonally-responsive human cancers with progestins and antiestrogens. In human endometrial cancer cell lines the antiproliferative effects of progestins and antiestrogens in a particular cell line appear to be associated with similar effects on growth factor and/or proto-oncogene expression. This suggests that although these compounds initially interact with different steroid hormone receptors, the molecular mechanisms of their growth inhibition may be essentially similar. In the case of human breast cancer cell lines, however, the effects of progestins and antiestrogens on gene regulation are often different, suggesting that the molecular mechanisms of progestin and antiestrogen growth inhibition may be essentially dissimilar.
Murphy
L C
LC
Department of Biochemistry and Molecular Biology, University of Manitoba, Winnipeg, Canada.
Dotzlaw
H
H
Alkhalaf
M
M
Coutts
A
A
Miller
T
T
Wong
M S
MS
Gong
Y
Y
Murphy
L J
LJ
D001943:Breast Neoplasms / Q000188:drug therapy*; D002455:Cell Division / Q000187:drug effects; D016889:Endometrial Neoplasms / Q000188:drug therapy*; D004815:Epidermal Growth Factor / Q000096:biosynthesis / Q000235:genetics; D004965:Estrogen Antagonists / Q000494:pharmacology*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D011372:Progestins / Q000494:pharmacology*; D000090063:Proto-Oncogene Mas; D011519:Proto-Oncogenes; D015291:Transforming Growth Factors / Q000096:biosynthesis / Q000235:genetics
D004965:Estrogen Antagonists; C000715470:MAS1 protein, human; D011372:Progestins; D000090063:Proto-Oncogene Mas; D004815:Epidermal Growth Factor; D015291:Transforming Growth Factors